aTyr Pharma, Inc. (ATYR) is a Biotechnology company in the Healthcare sector, currently trading at $0.84. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ATYR = $5 (+510.1% upside).
Valuation: ATYR trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.03.
Financials: revenue is $190,000, -49.7%/yr average growth. Net income is $74M (loss), growing at -18%/yr. Net profit margin is -39009.5% (negative). Gross margin is -717.4% (-801.1 pp trend).
Balance sheet: total debt is $12M against $67M equity (Debt-to-Equity (D/E) ratio 0.18, conservative). Current ratio is 5.3 (strong liquidity). Debt-to-assets is 12.8%. Total assets: $94M.
Analyst outlook: 2 / 9 analysts rate ATYR as buy (22%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).
